Demographics, follow up duration and coinfection characteristics of adults with chronic hepatitis B virus who died or were lost to follow-up vs who are active in the cohort
| Parameter . | Active . | Died . | Lost to follow-up . | P-value . | P-value lost to follow-up vs active . |
|---|---|---|---|---|---|
| n = 4363 . | n = 327 . | n = 1301 . | died vs active . | ||
| Follow-up duration, years, median [IQR] | 5.6 [3.8, 8.4] | 3.9 [1.9, 7.2] | 2.9 [1.5, 5.2] | <0.0001 | <0.0001 |
| Gender, male, n (%) | 2343 (53.7) | 256 (78.3) | 686 (52.7) | <0.0001 | 0.5580 |
| Age, years, median [IQR] | 40.0 [32.0, 50.0] | 58.0 [47.0, 68.0] | 35.0 [29.0, 44.0] | <0.0001 | <0.0001 |
| Age group, years, n (%) | <0.0001 | <0.0001 | |||
| 18–24 | 212 (4.9) | <5 (-) | 126 (9.7) | ||
| 25–34 | 1233 (28.3) | 14 (4.3) | 496 (38.1) | ||
| 35–44 | 1304 (29.9) | 47 (14.4) | 374 (28.7) | ||
| 45–54 | 894 (20.5) | 67 (20.5) | 190 (14.6) | ||
| 55–64 | 490 (11.2) | 85 (26.0) | 67 (5.1) | ||
| 65–74 | 184 (4.2) | 74 (22.6) | 39 (3.0) | ||
| >=75 | 46 (1.1) | 38 (11.6) | 9 (0.7) | ||
| Ethnic groups, n (%) | <0.0001 | <0.0001 | |||
| Asian | 1206 (27.6) | 77 (23.5) | 240 (18.4) | ||
| Black | 839 (19.2) | 58 (17.7) | 213 (16.4) | ||
| Mixed | 117 (2.7) | <5 (-) | 39 (3.0) | ||
| White | 1021 (23.4) | 126 (38.5) | 276 (21.2) | ||
| Other | 432 (9.9) | 27 (8.3) | 122 (9.4) | ||
| Not stated | 748 (17.1) | 36 (11.0) | 411 (31.6) | ||
| HCV coinfection, n (%) | 149 (3.4) | 49 (15.0) | 31 (2.4) | <0.0001 | 0.0762 |
| HDV coinfection, n (%) | 51 (1.2) | <5 (-) | 8 (0.6) | 0.8867 | 0.1160 |
| Past/acute HEV infection, n (%) | 33 (0.8) | 5 (1.5) | <5 (-) | 0.2366 | 0.0256 |
| HIV coinfection, n (%) | 78 (1.8) | 6 (1.8) | 13 (1.0) | 1 | 0.0629 |
| Parameter . | Active . | Died . | Lost to follow-up . | P-value . | P-value lost to follow-up vs active . |
|---|---|---|---|---|---|
| n = 4363 . | n = 327 . | n = 1301 . | died vs active . | ||
| Follow-up duration, years, median [IQR] | 5.6 [3.8, 8.4] | 3.9 [1.9, 7.2] | 2.9 [1.5, 5.2] | <0.0001 | <0.0001 |
| Gender, male, n (%) | 2343 (53.7) | 256 (78.3) | 686 (52.7) | <0.0001 | 0.5580 |
| Age, years, median [IQR] | 40.0 [32.0, 50.0] | 58.0 [47.0, 68.0] | 35.0 [29.0, 44.0] | <0.0001 | <0.0001 |
| Age group, years, n (%) | <0.0001 | <0.0001 | |||
| 18–24 | 212 (4.9) | <5 (-) | 126 (9.7) | ||
| 25–34 | 1233 (28.3) | 14 (4.3) | 496 (38.1) | ||
| 35–44 | 1304 (29.9) | 47 (14.4) | 374 (28.7) | ||
| 45–54 | 894 (20.5) | 67 (20.5) | 190 (14.6) | ||
| 55–64 | 490 (11.2) | 85 (26.0) | 67 (5.1) | ||
| 65–74 | 184 (4.2) | 74 (22.6) | 39 (3.0) | ||
| >=75 | 46 (1.1) | 38 (11.6) | 9 (0.7) | ||
| Ethnic groups, n (%) | <0.0001 | <0.0001 | |||
| Asian | 1206 (27.6) | 77 (23.5) | 240 (18.4) | ||
| Black | 839 (19.2) | 58 (17.7) | 213 (16.4) | ||
| Mixed | 117 (2.7) | <5 (-) | 39 (3.0) | ||
| White | 1021 (23.4) | 126 (38.5) | 276 (21.2) | ||
| Other | 432 (9.9) | 27 (8.3) | 122 (9.4) | ||
| Not stated | 748 (17.1) | 36 (11.0) | 411 (31.6) | ||
| HCV coinfection, n (%) | 149 (3.4) | 49 (15.0) | 31 (2.4) | <0.0001 | 0.0762 |
| HDV coinfection, n (%) | 51 (1.2) | <5 (-) | 8 (0.6) | 0.8867 | 0.1160 |
| Past/acute HEV infection, n (%) | 33 (0.8) | 5 (1.5) | <5 (-) | 0.2366 | 0.0256 |
| HIV coinfection, n (%) | 78 (1.8) | 6 (1.8) | 13 (1.0) | 1 | 0.0629 |
Square brackets for IQR, round brackets for % of column total.
IQR, interquartile range; HCV, hepatitis C virus; HDV, hepatitis D virus; HEV, hepatitis E virus; HIV, human immunodeficiency virus.
Demographics, follow up duration and coinfection characteristics of adults with chronic hepatitis B virus who died or were lost to follow-up vs who are active in the cohort
| Parameter . | Active . | Died . | Lost to follow-up . | P-value . | P-value lost to follow-up vs active . |
|---|---|---|---|---|---|
| n = 4363 . | n = 327 . | n = 1301 . | died vs active . | ||
| Follow-up duration, years, median [IQR] | 5.6 [3.8, 8.4] | 3.9 [1.9, 7.2] | 2.9 [1.5, 5.2] | <0.0001 | <0.0001 |
| Gender, male, n (%) | 2343 (53.7) | 256 (78.3) | 686 (52.7) | <0.0001 | 0.5580 |
| Age, years, median [IQR] | 40.0 [32.0, 50.0] | 58.0 [47.0, 68.0] | 35.0 [29.0, 44.0] | <0.0001 | <0.0001 |
| Age group, years, n (%) | <0.0001 | <0.0001 | |||
| 18–24 | 212 (4.9) | <5 (-) | 126 (9.7) | ||
| 25–34 | 1233 (28.3) | 14 (4.3) | 496 (38.1) | ||
| 35–44 | 1304 (29.9) | 47 (14.4) | 374 (28.7) | ||
| 45–54 | 894 (20.5) | 67 (20.5) | 190 (14.6) | ||
| 55–64 | 490 (11.2) | 85 (26.0) | 67 (5.1) | ||
| 65–74 | 184 (4.2) | 74 (22.6) | 39 (3.0) | ||
| >=75 | 46 (1.1) | 38 (11.6) | 9 (0.7) | ||
| Ethnic groups, n (%) | <0.0001 | <0.0001 | |||
| Asian | 1206 (27.6) | 77 (23.5) | 240 (18.4) | ||
| Black | 839 (19.2) | 58 (17.7) | 213 (16.4) | ||
| Mixed | 117 (2.7) | <5 (-) | 39 (3.0) | ||
| White | 1021 (23.4) | 126 (38.5) | 276 (21.2) | ||
| Other | 432 (9.9) | 27 (8.3) | 122 (9.4) | ||
| Not stated | 748 (17.1) | 36 (11.0) | 411 (31.6) | ||
| HCV coinfection, n (%) | 149 (3.4) | 49 (15.0) | 31 (2.4) | <0.0001 | 0.0762 |
| HDV coinfection, n (%) | 51 (1.2) | <5 (-) | 8 (0.6) | 0.8867 | 0.1160 |
| Past/acute HEV infection, n (%) | 33 (0.8) | 5 (1.5) | <5 (-) | 0.2366 | 0.0256 |
| HIV coinfection, n (%) | 78 (1.8) | 6 (1.8) | 13 (1.0) | 1 | 0.0629 |
| Parameter . | Active . | Died . | Lost to follow-up . | P-value . | P-value lost to follow-up vs active . |
|---|---|---|---|---|---|
| n = 4363 . | n = 327 . | n = 1301 . | died vs active . | ||
| Follow-up duration, years, median [IQR] | 5.6 [3.8, 8.4] | 3.9 [1.9, 7.2] | 2.9 [1.5, 5.2] | <0.0001 | <0.0001 |
| Gender, male, n (%) | 2343 (53.7) | 256 (78.3) | 686 (52.7) | <0.0001 | 0.5580 |
| Age, years, median [IQR] | 40.0 [32.0, 50.0] | 58.0 [47.0, 68.0] | 35.0 [29.0, 44.0] | <0.0001 | <0.0001 |
| Age group, years, n (%) | <0.0001 | <0.0001 | |||
| 18–24 | 212 (4.9) | <5 (-) | 126 (9.7) | ||
| 25–34 | 1233 (28.3) | 14 (4.3) | 496 (38.1) | ||
| 35–44 | 1304 (29.9) | 47 (14.4) | 374 (28.7) | ||
| 45–54 | 894 (20.5) | 67 (20.5) | 190 (14.6) | ||
| 55–64 | 490 (11.2) | 85 (26.0) | 67 (5.1) | ||
| 65–74 | 184 (4.2) | 74 (22.6) | 39 (3.0) | ||
| >=75 | 46 (1.1) | 38 (11.6) | 9 (0.7) | ||
| Ethnic groups, n (%) | <0.0001 | <0.0001 | |||
| Asian | 1206 (27.6) | 77 (23.5) | 240 (18.4) | ||
| Black | 839 (19.2) | 58 (17.7) | 213 (16.4) | ||
| Mixed | 117 (2.7) | <5 (-) | 39 (3.0) | ||
| White | 1021 (23.4) | 126 (38.5) | 276 (21.2) | ||
| Other | 432 (9.9) | 27 (8.3) | 122 (9.4) | ||
| Not stated | 748 (17.1) | 36 (11.0) | 411 (31.6) | ||
| HCV coinfection, n (%) | 149 (3.4) | 49 (15.0) | 31 (2.4) | <0.0001 | 0.0762 |
| HDV coinfection, n (%) | 51 (1.2) | <5 (-) | 8 (0.6) | 0.8867 | 0.1160 |
| Past/acute HEV infection, n (%) | 33 (0.8) | 5 (1.5) | <5 (-) | 0.2366 | 0.0256 |
| HIV coinfection, n (%) | 78 (1.8) | 6 (1.8) | 13 (1.0) | 1 | 0.0629 |
Square brackets for IQR, round brackets for % of column total.
IQR, interquartile range; HCV, hepatitis C virus; HDV, hepatitis D virus; HEV, hepatitis E virus; HIV, human immunodeficiency virus.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
